| Literature DB >> 32351822 |
Saba Laila Aslam1, Anwar Haque1, Muhammad Tariq Jamil2, Madiha Ariff3, Saad Nasir4.
Abstract
Objective Procedural sedation and analgesia are the standard of care for painful procedures in children that require immobility. The aim is to assess the safety and efficacy of procedural sedation and analgesia in pediatric oncological patients in a large tertiary care hospital. Method An observational study performed to review medical records of children who received procedural sedation and analgesia (PSA) for pediatric oncological procedures from July 2018 to September 2018. Patients undergoing oncology procedures (lumbar puncture, intrathecal chemotherapy, bone marrow aspiration +/- trephine) were included, and non-anesthesiologist (intensive care physician/emergency physician certified in pediatric advanced life support) provided PSA. Patients were assessed according to PSA protocol guidelines by the American Society of Anesthesiology (ASA). Low-dose ketamine (0.5 mg/kg) and propofol (2 mg/kg) were administered. Results A total of 565 children underwent 1216 procedures in whom the median age was 7.4 years, and the majority (65.1%) were males. The most common procedure was the lumbar puncture (n = 956; 78.6%) followed by bone marrow aspirate only (n = 137, 11.3%) and both (n = 123, 10.1%). Eight (0.7%) patients developed transient oxygen desaturation only as an adverse effect of ketamine-propofol drug combination with 50% procedures utilizing propofol 1 mg/kg for sedation. Conclusion According to the results of our study, the majority of the pediatric patients responded and reported no adverse events during the procedure with ketamine and propofol. Therefore, we conclude that ketamine and propofol are safe and effective as both sedative and an analgesic in procedures on pediatric oncology patients.Entities:
Keywords: efficacy; ketamine; procedural sedation and analgesia; propofol; safety
Year: 2020 PMID: 32351822 PMCID: PMC7186096 DOI: 10.7759/cureus.7442
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Characteristics of study participants
n, sample size; IQR, interquartile range
| Variable | n (%) |
| Age (Years) | |
| Median (IQR) | 7.4 (4.8-10.9) |
| Min – Max | 0.83-16 |
| Gender | |
| Male | 368 (65.1) |
| Female | 197 (34.9) |
| Total | 565 (100) |
| Procedure | |
| Bone marrow aspiration only | 137 (11.3) |
| Lumbar puncture only | 956 (78.6) |
| Bone marrow aspiration and lumbar puncture both | 123 (10.1) |
| Diagnosis | |
| Leukemia | 467 (82.7) |
| Lymphoma | 59 (10.4) |
| Sarcoma | 11 (1.9) |
| Other cancer | 24 (4.2) |
| Blood-related | 25 (4.4) |
| Propofol Doses (mg/kg) | |
| 1.0 | 675 (55.5) |
| 1.5 | 292 (24) |
| 2.0 | 162 (13.3) |
| 2.5 | 58 (4.8) |
| 3.0 | 17 (1.4) |
| 3.5 | 7 (0.6) |
| 4.0 | 5 (0.4) |
| Propofol Doses (mg/kg) | |
| Median (IQR) | 1 (1-1.5) |
| Min – Max | 1-4 |
| Adverse events | |
| Hypoxia | 8 (0.7) |
| None | 1208 (99.3) |
| Total | 1216 (100) |
Propofol levels in procedures (bone marrow aspiration, lumbar puncture or both)
Results are based on two-sided tests with a significance of level 0.05. For each significant pair, the key of the category with the larger median (a,b,c) appears under the category with the smaller median. *P-value <0.05, **P-value <0.0001, ¶ Kruskal–Wallis test
n, sample size; IQR, interquartile range
a, bone marrow aspiration only; b, lumbar puncture only; c, lumbar puncture and bone marrow aspiration both
| Propofol Doses (mg/kg) | P-value | |
| (Bone marrow aspiration only)a, n=137 | 0.000**¶ | |
| Mean ± Standard deviation | 2 ± 0.6 | |
| Median (IQR) | 2 (1.5-2.5) | |
| Min – Max | 1-4 | |
| (Lumber puncture only)b, n=956 | ||
| Mean ± Standard deviation | 1.2 ± 0.3 | |
| Med (IQR) | 1 (1-1.5) a,c | |
| Min – Max | 1-4 | |
| (Lumbar puncture and bone marrow aspiration both)c, n=123 | ||
| Mean ± Standard deviation | 2.1 ± 0.6 | |
| Med (IQR) | 2 (1.5-2.5) | |
| Min – Max | 1-4 | |